Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
1 report, 1 independent
Updated Aug 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
Mylan
former pharmaceutical company
Related events
- Barclays raised its price target on Latham Group on September 1, 2026.
- Barclays boosted its price target on Bunge on August 16, 2026.
- Barclays maintained Overweight rating and raised price target on August 29, 2025.
- Barclays issued rating and price objective reports for Ubiquiti on August 1, 2026.
- Barclays dropped its target price on TIM Group stock, while Santander Group and Scotiabank raised their price objectives for the company.